GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Open accessThe DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The 2 hormones responsible for the amplification of insulin secretion after oral as opposed to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). However, whereas GLP-1 also inhibits appetite and food intake and improves glucose regulation in patients with type 2 diabetes (T2DM), GIP seems to be devoid of these activities, although the 2 hormones as well as their receptors are highly related. In fact, numerous studies have suggested that GIP may promote obesity. However, chimeric peptides, combining elements of both peptides and capable of activating both receptors, have recently been demonstrated to have remarkable weight-losing and glucose-lowering efficacy in obese individuals with T2DM. At the same time, antagonists of the GIP receptor have been reported to reduce weight gain/cause weight loss in experimental animals including nonhuman primates. This suggests that both agonists and antagonist of the GIP receptor should be useful, at least for weight-losing therapy. How is this possible? We here review recent experimental evidence that agonist-induced internalization of the two receptors differs markedly and that modifications of the ligand structures, as in co-agonists, profoundly influence these cellular processes and may explain that an antagonist may activate while an agonist may block receptor signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a Phase 1 study, the addition of GIPR activity to GLP-1R/GCGR co-agonism was reported to greatly potentiate the weight-lowering and glycemic efficacy in overweight subjects (NCT04521738)153.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, GIPR agonism within multi-receptor agonists, improves bone metabolism153.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [153]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, GIP may enhance some of the effects of GLP-1 receptor agonism.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
The cited source says what the claim attributes to it.
In the citing paper
“Combination glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GIP RA are in development, and are illustrated by tirzepatide”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
The cited source says what the claim attributes to it.
In the citing paper
“Unless combined with GLP-1, it is unclear that GIP receptor agonism alone reduces hunger and reduces body fat.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [149]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 2×
“The insulinotropic effects of the other incretin hormone GLP-1 (14,15) and its possible incretin role (16), were described 1987.”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 2×
“patients with T2DM, while GIP is almost inactive (4).”
BackgroundSelf-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“Another important difference is that GLP-1 inhibits appetite and food intake (5), resulting in weight loss upon chronic administration, whereas GIP generally is thought to have no effects on food intake (6).”
BackgroundSelf-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The incretin effect is almost completely lost in people with type 2 diabetes (T2DM) and restoration of this deficiency would therefore be of great interest (2,3).”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 3×
“Around 1992, Raufman and Eng in New York characterized the Gila monster peptide exendin-4 (18), which turned out to be a full agonist for the GLP-1 receptor (19) (a synthetic version of which, exenatide, reached the market in 2005 (20)).”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Indeed, in 2002, mice with a knockout of the GIP receptor were demonstrated to be resistant to the adipogenic effect of a high-fat diet (42), and human genetic studies identified inactivating (Rosenkilde et al, unpublished) mutations in the GIP receptor, which were associated with weight loss (43).”
BackgroundSelf-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · cited 2×
“The insulinotropic effects of the other incretin hormone GLP-1 (14,15) and its possible incretin role (16), were described 1987.”
BackgroundNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“erance—their contribution (via insulin secretion) to postprandial glucose clearance may be as great as to correspond to 80% of the ingested amount of glucose (1).”
Background
Research works printed but not linked: 2
- Stensen S, Gasbjerg LS, Krogh LL, et al. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific effects in obese patients with type 2 diabetes. Diabetologia. 2019; 62: S270- S271.
- Marks V GIP: the obesity hormone. In: James WPT, Parker SW, eds. Current Approaches: Obesity. Southampton, England: Duphar Medical Relations; 1988: 13- 19.
Cited by
Items 101–200 of 208
Decoding the Significance of Alpha Cell Function in the Pathophysiology of Type 1 Diabetes
Carroll, J., Chen, J. Z.-J., Mittal, R., Lemos, J. R. N., Mittal, M., Juneja, S., Assayed, A., & Hirani, K. (2024) · Cells · doi:10.3390/cells13221914 · Cited by 21
“Currently, there is also potential in creating chimeric peptides of GIP and GLP-1 to modulate glucose control and weight loss in obese diabetic individuals [64].”
Green, C., Zaman, V., Blumenstock, K., Banik, N. L., & Haque, A. (2025) · Biomedicines · doi:10.3390/biomedicines13010132 · Cited by 13
“GIP is an incretin hormone that is involved in the regulation of lipid metabolism and the facilitation of fat deposition in the body [45,46].”
Enteroendocrine cell differentiation: Implications for human disease
Saint‐Denis, E., Frintu, B., Goldsmith, M., Ramos, G. P., & Zeve, D. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112607 · Cited by 12
The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection
Lindquist, P., Gasbjerg, L. S., Mokrosiński, J., Holst, J. J., Hauser, A. S., & ROSENKILDE, M. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.891586 · Cited by 11
Self-citationLyu, X., Yan, K., Hu, W., Xu, H., Guo, X., Zhou, Z., Zhu, H., Pan, H., Wang, L., Yang, H., et al. (2023) · Phytotherapy Research · doi:10.1002/ptr.7788 · Cited by 13
“Owing to the inability to promote insulin secretion in patients with type 2 diabetes mellitus (T2DM), GIP has not been developed as a drug for the treatment of T2DM like glucagon-like peptide 1 (GLP-1) (Holst & Rosenkilde, 2020).”
Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion
Xu, Y., Michalowski, C. B., Koehler, J. A., Darwish, T., Guccio, N., Alcaino, C., Domingues, I., Zhang, W., Marotti, V., Hul, M. V., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq9909 · Cited by 10
“Both GIP agonists and GIP antagonists represent promising treatments in the field of metabolic disorders ( 37 , 38 ).”
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity
Pati, B., Sendh, S., Sahu, B., Pani, S., Jena, N., & Bal, N. C. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00107e · Cited by 10
What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
Holst, J. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100284 · Cited by 9
“In addition, for unknown reasons, GIP loses most of its insulinotropic effect in diabetes patients and may be diabetogenic, because it retains a stimulatory effect on glucagon secretion.(4) Accordingly, various attempts have been made to antagonize the actions of GIP to prevent fat accumulation, and among the most suc…”
BackgroundSelf-citationPolyagonists in Type 2 Diabetes Management
Dissanayake, H. A., & Somasundaram, N. P. (2024) · Current Diabetes Reports · doi:10.1007/s11892-023-01530-2 · Cited by 8
“The overwhelming success of tirzepatide may at least partly be due to such a structural uniqueness that leads to decreased receptor down regulation at one or both receptors [21].”
The unexpected role of GIP in transforming obesity treatment
Zandvakili, I., & Pérez–Tilve, D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.022 · Cited by 9
Giofrè, F., Zaffina, I., Pelle, M. C., & Arturi, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696419 · Cited by 12
Pharmacotherapy for chronic obesity management: a look into the future
Abdel-Malek, M., Yang, L., & Miras, A. D. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03237-4 · Cited by 14
“When results are compared across studies, it seems that GIP agonism and antagonism produce similar changes in body weight and both agonists and antagonists achieve synergistic weight loss when combined with GLP-1 agonists [20].”
BackgroundNeuroendocrine Control of Body Energy Homeostasis
Affinati, A. H., & Myers, M. G. (2021) · Europe PMC (PubMed Central) · Cited by 17
Atamni, H. J. A., Lone, I. M., Binenbaum, I., Mott, R., Pilalis, E., Chatziioannou, A. A., & Iraqi, F. A. (2023) · Mammalian Genome · doi:10.1007/s00335-023-10025-0 · Cited by 7
“GIP – also known as glucose-dependent insuli-notropic polypeptide—is responsible for insulin secretion in response to nutrients and is a high interest therapeutic target in diabetes and obesity (reviewed in Holst and Rosenkilde 2020).”
Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
“Holst and Rosenkilde [63] noted that the first co-agonist NN9709 did not differ from liraglutide in a phase 2 study [44].”
Liu, X., Liu, X., Hu, Y., Wang, X., Yang, X., Bin, Y., Zhou, Y., Zhou, L., Fan, G., & Yang, J. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf022 · Cited by 5
“These promising discoveries have paved the way for the development of therapies based on GIP receptor agonists or strategies aimed at enhancing the endogenous secretion of GIP for the treatment of T2DM [10].”
Effect of Laparoscopic Sleeve Gastrectomy on HbA1C Level in Children with Type 2 Diabetes Mellitus
Asiri, A., Alzahrani, F., Alghamdi, H., & Alamri, Z. (2022) · Medicina · doi:10.3390/medicina58070959 · Cited by 7
Tordrup, E. K., Gadgaard, S., Windeløv, J. A., Holst, J. J., Gasbjerg, L. S., Hartmann, B., & ROSENKILDE, M. M. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116893 · Cited by 7
Self-citationAlavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
“…hormones and their receptors, recent studies have shown that chimeric peptides, which combine components of both hormones and can activate both receptors, have demonstrated significant effectiveness in promoting weight loss and lowering glucose levels in preclinical and clinical settings [59].”
Rees, T. A., Buttle, B., Tasma, Z., Yang, S.-H., Harris, P. W. R., & Walker, C. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1463313 · Cited by 10
Biotechnology Revolution Shaping the Future of Diabetes Management
Kundnani, N. R., Lolescu, B. M., Dinu, A. R., Berceanu-Vaduva, D. M., Dumitrescu, P., Tamaș, T.-P., Sharma, A., & Popa, M.-D. (2024) · Biomolecules · doi:10.3390/biom14121563 · Cited by 7
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Milhouse, W., Organski, A. C., Sun, X., Ai, D., Zhou, B., Cross, T.-W., & Ren, H. (2025) · Physiological Reports · doi:10.14814/phy2.70373 · Cited by 5
“The anorexigenic effects of Glp-1 are more widely supported, while the effect of Gip on food intake, although currently unclear, has been suggested to be minimal (Holst & Rosenkilde, 2020).”
Diabetic Foot - Recent Advances
Raghav, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102211 · Cited by 5
Rathnam, S. S., Deepak, T., Sahoo, B. N., Meena, T., Singh, Y., & Joshi, A. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001689 · Cited by 7
Cosmetic Considerations of Semaglutide
Baggett, A. D., Saadi, C. C., Saadi, R. A., & Patel, V. (2025) · Cosmetics · doi:10.3390/cosmetics12050221 · Cited by 6
Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration
Yang, X., Lin, R., Feng, C., Kang, Q., Yu, P., Deng, Y., & Jin, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111353 · Cited by 6
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
Lian, K., Zhang, K., Kan, C., Hou, N., Han, F., Sun, X., Qiu, H., & Guo, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122801 · Cited by 6
Lahey, A. M., Duprey, K. S., Montague, R. C., Schadler, A. D., & Naseman, K. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70009 · Cited by 6
Effects of patient age on the therapeutic effects of GIP/GLP-1 receptor agonists (tirzepatide)
Ishimura, A., Shimizu, Y., & Yabuki, N. (2025) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2025.01012 · Cited by 4
Novel approaches to pharmacological management of type 2 diabetes in Japan
Kaneko, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1974401 · Cited by 6
Kytikovа, O. Y., Denisenko, Y., Novgorodtseva, T. P., Antonyuk, M. V., & Gvozdenko, T. A. (2022) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn1608 · Cited by 4
“Данный инсулинотропный пептидный гормон продуцируется L-клетками слизистой оболочки толстой и подвздошной кишок и воздействует не только на поджелудочную железу, но и на другие органы и системы [74].”
Evolution and therapeutic potential of glucagon-like peptide 2 analogs
Binbin, G., Wang, T., & Sun, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116758 · Cited by 4
Nguyen, A., Khafagy, R. T. M., Meerasa, A., Roshandel, D., Paterson, A. D., & Dash, S. (2022) · Diabetes · doi:10.2337/db22-0138 · Cited by 6
Druzhilov, М. A., Kuznetsova, Т. Y., & Chumakova, G. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4755 · Cited by 5
Alnagar, A., Sinha, Y., Ahmad, A. N., Ahmed, A., & Noormohamed, M. S. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00640-0 · Cited by 4
“Holst and Rosenkilde (2020) elaborated on the synergistic effects of GLP-1 and GIP receptor activation, resulting in enhanced metabolic benefits and sustained weight loss [ 11].”
Franklin, Z. J., Lafferty, R. A., Flatt, P. R., McShane, L. M., O'Harte, F. P. M., & Irwin, N. (2022) · Biochimie · doi:10.1016/j.biochi.2022.04.005 · Cited by 4
“Whereas on the other hand, activation of receptors for GIP also exhibits positive effects, both alone [38,39] and together with concurrent GLP-1 receptor activation [33,34,40].”
BackgroundPharmacology of Gut Hormone Mimetics for Obesity and Diabetes
Lafferty, R. A., O'Harte, F. P. M., Irwin, N., Flatt, P. R., & Gault, V. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00035-9 · Cited by 3
West, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/822122 · Cited by 3
Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
Soliman, S., Andrews‐Dickert, R., Ročić, P., & Mitov, M. I. (2025) · Pharmaceuticals · doi:10.3390/ph18101519 · Cited by 3
“These include the route of administration and site of action [18,19], dosage [20], species differences (rodents vs. humans) [21], and metabolic context, such as obesity or type 2 diabetes [22].”
Effects of incretin drugs on glycemic control and body weight
Levitskaya, A. N., Demidova, T. Y., & Геннадьевна, Л. К. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-07 · Cited by 2
Çelik, M. N., & Uluğ, E. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01961-9 · Cited by 2
Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health
Tariq, A., Gangemi, A., & Herrera-Caceres, J. O. (2026) · Urology Case Reports · doi:10.1016/j.eucr.2026.103368 · Cited by 4
GIPR signaling modulates PYY-induced hypophagia and malaise in rodents
Borner, T., Pataro, A. M., Curtis, G. R., Alonso, B., Hu, J., Fortin, S. M., Koul‐Tiwari, R., Hughes, E. A. G., Kong, J., Jordan, E., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102334 · Cited by 2
“Despite a growing body of literature on GIP physiology, there still is limited and contentious pre-clinical and clinical data on the potential application of GIP analogs for the treatment of metabolic disease (see [52 — 55] for review).”
Harnessing the Incretin System with Multi-Agonists
Whyte, M., Heald, A. H., & Field, B. C. T. (2022) · EMJ Innovation · doi:10.33590/emjinnov/10115628 · Cited by 2
Effect of switching from dulaglutide to tirzepatide on blood glucose and renal function
Ishimura, A., & Kumakura, H. (2024) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2024.01061 · Cited by 2
Gut-brain axis: The role of gut microbiota in energy balance and body weight regulation
Tatık, G. P., Baran, Ö., & Dağ, A. (2025) · Clinical Science of Nutrition · doi:10.62210/clinscinutr.2024.98 · Cited by 5
“19 GLP-1 can also modulate satiety: Chronic treatment with Glucagon-like peptide-1 receptor (GLP1R) agonists (compounds that bind to cell receptors to create a response in the cell) in the long-term control of food intake serves to suppress food intake and promote weight loss.”
InfluentialThe Relevance of Metabotrophic Factors in Pathobiology and Therapy of Obesity and Related Diseases
Chaldakov, G. N., Aloe, L., Rančić, G., Pancheva, R., Hiriart, M., Fiore, M., & Yanev, S. G. (2021) · Advances in biochemistry in health and disease · doi:10.1007/978-3-030-84763-0_16 · Cited by 2
Mitigating Diabetic Foot Ulcers: The Effect of Diet and Microbiome
Coon, S. D. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106629 · Cited by 2
A „másik” inkretin – a glükózdependens insulinotrop polipeptid terápiás újrafelfedezése
Winkler, G., Kis, J. T., & Schandl, L. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32710 · Cited by 5
Gut-derived peptide hormone receptor expression in the developing mouse hypothalamus
Cantacorps, L., Coull, B. M., Falck, J. E., Ritter, K., & Lippert, R. N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0290043 · Cited by 4
Adeyomoye, O., Adetunji, J. B., Olaniyan, O. T., Adetunji, C. O., & Oluwafemi, D. Y. (2024) · Phytomedicine Plus · doi:10.1016/j.phyplu.2024.100594 · Cited by 2
Médicaments anti-obésité : leçons des échecs pour l’avenir
Scheen, A. J. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.012 · Cited by 4
Effects of whey protein on appetite: An overview with a mechanistic insight
Nouri, M. (2022) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/2065 · Cited by 1
“WP may help in decreasing food intake by preserving GIP [11].”
BackgroundThe role of incretins in gestational diabetes: a case-control study on the impact of obesity
Yurtçu, E., Keyif, B., Yılmaz, G., Erkılınç, S., Akkaya, H., & Ozgu-Erdinc, A. S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01483-w · Cited by 3
“However, as the evidence increased, it was shown that the incretin effect was partially attenuated even after immunoneutralization of GIP, indicating that GIP is not the only intestinal-derived incretin [20, 21].”
BackgroundEgelandsdal, B., Haug, A., Rehfeld, J. F., Coutinho, S. R., Ricart, L. R., Martens, H. A., Monfort‐Pires, M., & Martins, C. (2025) · Nutrients · doi:10.3390/nu17091581 · Cited by 1
“On the other hand, in people with type 2 diabetes, the incretin effect—including GIP response—is almost entirely lost [62].”
Hookey, T., Backus, R. C., Bjørnvad, C. R., Davison, L. J., Fleeman, L. M., Fracassi, F., German, A. J., Gilor, C., Gostelow, R., Schoeman, T., et al. (2025) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x251409019 · Cited by 3
“71 The net effect of increasing fat ingestion is a reduced rate of glucose entry from the intestine, potentiation of insulin secretion and inhibition of glucagon release.”
Li, Z., Wang, X., He, Y., Hu, K., Liu, Y., Zhang, W., Ma, Y., & Jiang, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1754925 · Cited by 2
“GIP is another key incretin hormone predominantly expressed in adipose tissue, where it participates in glucose uptake, lipolysis, and regulation of lipoprotein lipase activity (22).”
Mitochondrial dysfunction and lipid droplet dynamics in MASH: HSD17B13 as a therapeutic target
Noor, S., Tian, Y., & Su, W. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1912237 · Cited by 1
“Because GLP-1 receptor expression in hepatocytes is low, its hepatic effects are thought to arise predominantly through extrahepatic actions involving the pancreas, central nervous system, gastrointestinal tract and cardiovascular system (Drucker, 2018; Holst et al., 2020).”
Advances in the Management of Diabetes and Overweight using Incretin-based Pharmacotherapies
Prajapati, S. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998256797231009062744 · Cited by 1
Самойлова, Ю. Г., Ваизова, О. Е., Stankova, A. E., Матвеева, М. В., Подчиненова, Д. В., Kudlay, D. A., Borozinets, A. A., Filippova, T. A., Романович, Г. И., Partala, A. V., et al. (2024) · Terapevticheskii arkhiv · doi:10.26442/00403660.2024.01.202553 · Cited by 2
Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview
Davies, C. (2025) · Nursing Standard · doi:10.7748/ns.2025.e12464 · Cited by 1
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
“Compounds with dual GLP1RA/GIPRA activity have been developed, and it has been suggested that even when the specific contribution of the GIPRA to weight loss is unclear, it may promote weight loss by modulating GLP‑1 signaling (79).”
Cross-ethnic Molecular Signatures Underpin the Adverse Impact of Statin Use on Type 2 Diabetes
Xu, F., Yang, M., Hu, W., Yuan, S., Cai, X., Gou, W., Miao, Z., Li, B., Yue, L., Xue, Z., et al. (2025) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzaf101 · Cited by 2
“GIP is a hormone secreted by enteroendocrine cells in the gastrointestinal tract [31,32].”
Incretin Analogues in Therapy of Type 2 Diabetes and Obesity
Zalunin, I. A., Asrarkulova, A. S., & Kozlov, D. G. (2021) · Biotekhnologiya · doi:10.21519/0234-2758-2021-37-3-53-64 · Cited by 1
Incretin Analogues in the Therapy of Type 2 Diabetes and Obesity
Bulushova, N. V., Zalunin, I. A., Asrarkulova, A. S., & Kozlov, D. G. (2022) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683822070031 · Cited by 1
“The percentage of the interlized protein can depend on the ligand structure (analogue used), which makes it difficult to compare the results [43].”
BackgroundMethodInfluentialTirzepatide Reduced Significantly the Body Weight in Obese Patients
Gerő, L. (2022) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2022.16.555930 · Cited by 1
Tirzepatide: A Useful Addition for Treatment of Type 2 Diabetes and Obesity
Mikhail, N. (2021) · Gastroenterology Pancreatology and Hepatobilary Disorders · doi:10.31579/2641-5194/044
Secretion and Impact of Gut Hormones in Obesity and Diabetes
Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9
Self-citationGlucagon-related advancements in diabetes therapy
Sinha, B., Ghosal, S., Mukhopadhyay, S., Hussain, A., Mohan, A. R., Schwarz, P. E. H., & Cos, X. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_96_23 · Cited by 1
Multi‐target Peptides for the Treatment of Metabolic Diseases
Bossart, M., & Heßler, G. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch20
Greener, M. (2025) · Independent Nurse · doi:10.12968/indn.2025.2.8
The obesity-linked peptide SP16 regulates adipocytes through GIP and insulin receptorPreprint
Ngo, T. M. H., Santhanam, R., Teufel, D. P., Dick, A., Lam, D. D., Klein, H., Brunner, A., Pereira, M. M. A., Bartelt, A., Pekcec, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.17.660082
Prosecký, R., & Karoliová, K. H. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.041
Effect of Tirzepatide on Cardiovascular Outcomes
Huston, J., Orey, D., Ashchi, A., Lachapelle, A. A., Genovese, A., Jackson, J., Ashchi, R., Ashchi, T., Ashchi, M., Sutton, D., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00767-4 · Cited by 1
“Chimeric peptides, combining elements of both peptides and capable of activating both receptors, have recently been demonstrated to have remarkable weight-loss and glucose-lowering efficacy in people with obesity and T2DM [9].”
CREATION OF THE PREGNANCY MICE MODEL TO STUDY THE EFFECT OF GLP-1/GIP AGONISTS
Akylzhanova, G., Bakenova, O., Abetov, D. A., Umarov, A., Musaeva, Z., Akilzhanova, G. A., Sarbassov, D. D., & Akilzhanova, A. R. (2025) · Ġylym men densaulyķ saķtau. · doi:10.34689/sh.2025.27.4.008
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26633796
Boutari, C., Stefanakis, K., Simati, S., Guatibonza-García, V., Valenzuela‐Vallejo, L., Anastasiou, I. A., Connelly, M. A., Kokkinos, A., & Mantzoros, C. S. (2024) · Figshare · doi:10.6084/m9.figshare.26722629
Sraboni, A., Farhana, K. M., & Abdul, M. K. (2026) · Review of Medicine Surgery and Dentistry · doi:10.64907/xkmf.v5.i1.rmsd.1
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
The evolution of obesity pharmacotherapy from sympathomimetics to incretin-based therapies
Ncube, K. N., Moloi, N., & Malange, T. D. (2026) · SA pharmaceutical journal. · doi:10.36303/sapj.4108 · Cited by 1
Wu, Y., Hashemy, H., Paterson, A. D., & Dash, S. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.03.001
Andrews, K. E., Sibthorpe, P. E. M., Fitzgerald, D. M., & de Laat, M. A. (2026) · The Veterinary Journal · doi:10.1016/j.tvjl.2026.106644
The effect of liraglutide on overweight and streptozotocin-induced diabetic male rats
Hafth, H. A., Alwan, N. A., & AL-MASOUDI, E. A. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.2.2026.1691
Α-gustducine intestinale : implication dans l'obésité et le diabète de type 2
Gléau, L. L. (2021) · theses.fr (ABES) · doi:10.70675/dc436e75zb6d2z4bb4zb9a1z17b025f205a6
Chasseloup, F. (2022) · theses.fr (ABES) · doi:10.70675/ddec5b6dzf376z4aadz9970zf0bf052c6f02
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-9783878/v1
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
“Recently, it has been discovered that the co-activation of GIP and GLP-1 receptors can overcome GIP resistance, restore physiological insulin secretion, and improve overall insulin sensitivity [86,87].”
InfluentialVignera, S. L., Fioriglio, C., & Condorelli, R. A. (2026) · Diagnostics · doi:10.3390/diagnostics16131979
“GLP-1 and GIP are the two principal incretin hormones, secreted by intestinal enteroen-docrine cells (L-cells and K-cells, respectively) in response to nutrient ingestion [19,20].”
Patel, H., Babli, S. A., Shah, S., Khambholja, S. H., Lingadahalli, T. D., Villarson, C., Rizwanullah, U., Kumarsivarajah, S., Masood, A., Rahming, N., et al. (2026) · Cureus · doi:10.7759/cureus.111786
“Without a reliable pooled estimate of expected regain, prescribers cannot adequately counsel patients, and healthcare systems cannot model the cost implications of intermittent or short-course prescribing [25,35].”
Sun, Y., Xie, C., Huang, W., Bound, M. J., Grivell, J., Jones, K. L., Horowitz, M., Macdonald, I. A., Rayner, C. K., & Wu, T. (2026) · Diabetes · doi:10.2337/db26-0267
Li, Y., Ye, D., Fu, C., Huang, X., Ma, Q., Zhang, F., Chen, G., Song, P., Kong, C., Wu, J., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2687937
“A central controversy in incretin biology concerns whether GIP agonism or antagonism confers metabolic benefit, 28 and emerging evidence indicates that they exert their effects through distinct mechanisms.”
Rivera‐Gonzalez, O., Liu, L., Gribble, F. M., Reimann, F., & Wess, J. (2026) · Science Advances · doi:10.1126/sciadv.aeb9805
Udomsinprasert, W. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2708824
Agonists and Antagonists of the Human GIP Receptor
Kizilkaya, H. S., Gasbjerg, L. S., Holst, J. J., & Rosenkilde, M. M. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch2
Self-citation
Metadata
- Authors
- Holst, J. J., & Rosenkilde, M. M.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, Jens Juul
- Rosenkilde, Mette Marie
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-05-27
- Volume
- 105
- Issue
- 8
- Pages
- e2710-e2716
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC7308078
- OpenAlex
- W3030023482
- Cited by
- 207
- References
- 60
- Citations by year
- 2026: 32 · 2025: 36 · 2024: 39 · 2023: 28 · 2022: 40 · 2021: 26 · 2020: 4
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP receptor, type 2 diabetes, obesity, GIP receptor antagonist, receptor internalization, ligand structure, insulin secretion, weight loss treatment, receptor signaling
- MeSH terms
- Appetite, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Receptors, Gastrointestinal Hormone, Signal Transduction, Weight Loss, Anti-Obesity Agents, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.